Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Fluid retention is a common adverse event in patients who receive endothelin (ET) receptor antagonist therapy, including the highly selective ETA receptor antagonist, atrasentan. OBJECTIVE: We performed longitudinal assessments of thoracic bioimpedance in patients with type 2 diabetes me...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, David J., Coll, Blai, Heerspink, Hiddo J. L., Andress, Dennis, Pritchett, Yili, Brennan, John J., Houser, Mark, Correa-Rotter, Ricardo, Kohan, Donald, Makino, Hirofumi, Perkovic, Vlado, Remuzzi, Giuseppe, Tobe, Sheldon W., Toto, Robert, Busch, Robert, Pergola, Pablo, Parving, Hans-Henrik, de Zeeuw, Dick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629141/
https://www.ncbi.nlm.nih.gov/pubmed/28831752
http://dx.doi.org/10.1007/s40268-017-0201-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629141/
https://www.ncbi.nlm.nih.gov/pubmed/28831752
http://dx.doi.org/10.1007/s40268-017-0201-0

Ejemplares similares